HEMO
GOODHemogenyx Raises £570,000 to Continue Phase 1 Trials
The biotechnology company has secured £570,000 in funding to continue Phase 1 trials for its lead cancer treatment candidate.
Hemogenyx Pharmaceuticals
345.00GBX
7.81%
Market Cap
16.31M
Volume
289.13k
566% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.62
Day Range
310.00p - 370.00p
52 Week Range
124.00p345.00p1,200.00p
345.00p
Upcoming Events
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on HG-CT-1 CAR-T Therapy Trial
The biotechnology company reports progress in its clinical trial for a new CAR-T therapy to treat a form of blood cancer.
HEMO
BADHemogenyx Secures £250,000 to Continue Phase 1 Trials
The biotechnology company has raised £250,000 through a discounted share placement to continue its Phase 1 clinical trials, but the significant discount indicates potential challenges.
HEMO
GOODHemogenyx Awarded $120,000 Grant to Optimize CAR-T Manufacturing
The biotechnology company has been awarded a grant to optimize the manufacturing process for its lead CAR-T therapy, which is expected to improve cost-effectiveness and scalability.
HEMO
NEUTRALHemogenyx Pharmaceuticals Receives Clearance to Expand Pediatric Enrollment in AML Trial
The biotechnology company has received regulatory clearance to expand its ongoing clinical trial of a CAR-T therapy for a rare blood cancer to include pediatric patients.
HEMO
GOODHemogenyx Secures £451,250 to Continue Phase 1 Trials
The biotechnology company has secured £451,250 in funding to continue its Phase I clinical trials for a key therapy, with the raise priced at a premium to the previous share price.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on HG-CT-1 CAR-T Therapy Trial
The biotechnology company reports successful treatment of a second patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients
The biotechnology company has filed an amendment to include children and adolescents with relapsed/refractory acute myeloid leukemia in its ongoing Phase I clinical trial for its CAR-T therapy HG-CT-1.
HEMO
NEUTRALHemogenyx Pharmaceuticals Corrects AGM Resolutions
The biotechnology company has issued a correction to the resolutions in its recent AGM notice, fixing a clerical error related to the authorities sought by the directors.
HEMO
GOODHemogenyx Secures £451,250 to Continue Phase 1 Trials
The biotechnology company has raised £451,250 to continue its Phase I clinical trials for a new cancer treatment, with the funds secured at a small 1.6% discount to the previous share price.